Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Transplant Cell Ther. 2020 Oct 11;27(1):84.e1–84.e5. doi: 10.1016/j.bbmt.2020.10.008

Figure 3.

Figure 3.

OS in the foscarnet and no foscarnet groups. The 6-month OS was 96% in the foscarnet group (95% CI, 74% to 99%) and 72% in the control group (95% CI, 59% to 82%).